NCT03773302
Clinical Trial Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT03773302 |
| Title | Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations |
| Recruitment | Terminated |
| Gender | both |
| Phase | Phase III |
| Variant Requirements | Yes |
| Sponsors | QED Therapeutics, Inc. |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS |
CKB BOOST